Squarepoint
IOVA icon

Squarepoint’s Iovance Biotherapeutics IOVA Stock Holding History

Squarepoint’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,500
Closed -$115K – 4991
2024
Q4 		$115K Buy
+15,500
New +$144K ﹤0.01% 4663

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Squarepoint's IOVA Position: Q2 2026 in Review

Squarepoint reduced its Iovance Biotherapeutics (IOVA) stake by 68% in Q2 2026, selling an estimated $2.68M and leaving 325,582 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2653.

Squarepoint first reported a position in IOVA in Q3 2017 and has held it in 30 quarters since. The position peaked at $3.62M in Q1 2026. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Squarepoint held 325,582 shares of Iovance Biotherapeutics worth $1.35M as of Q2 2026.
  • Squarepoint sold 706,586 Iovance Biotherapeutics shares in Q2 2026, an estimated $2.68M.
  • Iovance Biotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2653 holding.
  • Squarepoint first reported a position in Iovance Biotherapeutics in Q3 2017 and has held it in 30 quarters since.
  • Squarepoint's Iovance Biotherapeutics position peaked at $3.62M in Q1 2026.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.